Response and survival of dogs with proteinuria (UPC > 2.0) treated with angiotensin converting enzyme inhibitors
Journal of Veterinary Internal Medicine · 2023
DOI: 10.1111/jvim.16864 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Veterinary Internal Medicine, 2023. Verfasst von Emily A Fulton und 3 weiteren Autor:innen. Beteiligte Einrichtung: The University of Glasgow Small Animal Hospital, School of Biodiversity, One Health and Veterinary Medicine, 464 Bearsden Road, Glasgow G61 1QH, Unit…. Hauptthemen laut MEDLINE: Hypoalbuminemia, Azotemia, Dog Diseases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Angiotensin-converting enzyme inhibitors (ACEi) are a recommended treatment for glomerular proteinuria. Frequency of response to ACEi and the association of achieving proposed urine protein-to-creatinine ratio (UPC) targets on survival is unknown.
Objectives
To determine response rates to ACEi therapy and whether a positive response is associated with improved survival. Animals Eighty-five dogs with proteinuria (UPC > 2.0).
Methods
Retrospective study including dogs (UPC > 2.0) prescribed an ACEi for treatment of proteinuria. Baseline creatinine, albumin, cholesterol, UPC, and systolic blood pressure were recorded, and cases reviewed to track UPC. Treatment response was defined as achieving a UPC of <0.5 or reduction of ≥50% from baseline within 3 months. Outcome data were collected to determine overall and 12-month survival.
Results
Thirty-five (41%) dogs responded to ACEi treatment. Treatment response was statistically associated with both median survival time (664 days [95% confidence interval (CI): 459-869] for responders compared to 177 [95% CI: 131-223] for non-responders) and 12-month survival (79% responders alive compared to 28% non-responders). Baseline azotemia or hypoalbuminemia were also associated with a worse prognosis, with odds ratios of death at 12 months of 5.34 (CI: 1.85-17.32) and 4.51 (CI: 1.66-13.14), respectively. In the 25 dogs with normal baseline creatinine and albumin, response to treatment was associated with 12-month survival (92% responders alive compared to 54% non-responders, P = .04). Conclusions and Clinical Importance When the UPC is >2.0, achieving recommended UPC targets within 3 months appears to be associated with a significant survival benefit. Response to treatment is still associated with survival benefit in dogs with less severe disease (no azotemia or hypoalbuminemia).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The University of Glasgow Small Animal Hospital, School of Biodiversity, One Health and Veterinary Medicine, 464 Bearsden Road, Glasgow G61 1QH, United Kingdom.
- VetsNow Hospital Glasgow, 123-145 North Street, Glasgow G3 7DA, United Kingdom.
- Royal (Dick) School of Veterinary Studies, The University of Edinburgh, Easter Bush Campus, Roslin EH25 9RG, United Kingdom.
ORCID-Profile: Emily A Fulton
Zitieren
APA
Fulton, E. A., McBrearty, A. R., Shaw, D. J., & Ridyard, A. E. (2023). Response and survival of dogs with proteinuria (UPC > 2.0) treated with angiotensin converting enzyme inhibitors. Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.16864
Vancouver
Fulton EA, McBrearty AR, Shaw DJ, Ridyard AE. Response and survival of dogs with proteinuria (UPC > 2.0) treated with angiotensin converting enzyme inhibitors. Journal of Veterinary Internal Medicine. 2023. doi:10.1111/jvim.16864
BibTeX
@article{Fulton2023,
author = {Fulton, Emily A and McBrearty, Alix R and Shaw, Darren J and Ridyard, Alison E},
title = {Response and survival of dogs with proteinuria (UPC > 2.0) treated with angiotensin converting enzyme inhibitors},
journal = {Journal of Veterinary Internal Medicine},
year = {2023},
doi = {10.1111/jvim.16864}
}
EUVIMED